Actively Recruiting
Nasal Antisepsis for C. Auris Prevention
Led by Mary K Hayden · Updated on 2025-10-15
120
Participants Needed
3
Research Sites
252 weeks
Total Duration
On this page
Sponsors
M
Mary K Hayden
Lead Sponsor
R
Rush University Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
CONDITIONS
Official Title
Nasal Antisepsis for C. Auris Prevention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of C. auris colonization or infection
- Patient in a participating facility
You will not qualify if you...
- History of severe allergy to iodine-based products, defined as anaphylaxis or rash
- Currently breastfeeding or pregnant
- Non-English language speaking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Rush University Medical Center
Chicago, Illinois, United States, 60612
Actively Recruiting
2
RML Specialty Hospital
Chicago, Illinois, United States, 60624
Actively Recruiting
3
RML Specialty Hospital
Hinsdale, Illinois, United States, 60521
Actively Recruiting
Research Team
S
Sarah E. Sansom, DO
CONTACT
M
Mary K. Hayden, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here